NASDAQ$CYPH
Cypherpunk Technologies Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Leap Therapeutics reported financial results for the first quarter of 2023.
Leap Therapeutics reported a net loss of $41.9 million for the first quarter of 2023, primarily due to in-process research & development (IPR&D) expense associated with the acquisition of Flame Biosciences. They are in a strong financial position to develop their pipeline of personalized medicines for cancer patients.
- Completed enrollment in Part A of the DeFianCe second-line CRC study.
- Made excellent progress in enrolling in Part C of the DisTinGuish first-line GEA study.
- Will present long-term follow-up data from Part A of the DisTinGuish study at ASCO in June.
- Acquired Flame Biosciences at the beginning of the year.
Headline financials
Revenue & EPS history
Leap Therapeutics · Revenue · Quarterly
$0
Forward guidance
Leap Therapeutics' forward-looking statements involve risks and uncertainties, including clinical trial execution, regulatory approvals, strategic partnerships, and financial stability.
Tailwinds
- Continuation of clinical collaboration with BeiGene.
- Expected benefits from the merger with Flame Biosciences.
- Potential for new strategic partnerships for DKN-01.
- Anticipated timing for initiation or success of enrollment in clinical trials.
- Potential, safety, efficacy, and regulatory and clinical progress of Leap’s product candidates.
Headwinds
- Ability to successfully execute clinical trials.
- Results of clinical trials and pre-clinical studies.
- Ability to successfully enter into new strategic partnerships.
- Approval from regulatory agencies.
- Sufficiency of cash resources to fund operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+11.8%
Avg return
Earnings day
+13.6%
Avg return
5 days after
+11.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+389.9%
Q3 2025
Best reaction
-44.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +389.9% | +454.8% | +228.8% | |
| Q2 2025 | -28.3% | -15.6% | -11.8% | |
| Q1 2025 | -2.5% | -12.4% | -0.5% | |
| Q4 2024 | +16.9% | -21.4% | +3.1% | |
| Q3 2024 | -11.1% | -14.5% | -9.2% | |
| Q1 2024 | -1.1% | -5.4% | -22.1% | |
| Q4 2023 | -0.5% | +14.0% | +35.7% | |
| Q3 2023 | +13.0% | +32.6% | +128.3% | |
| Q2 2023 | +7.6% | -8.9% | -28.4% | |
| Q1 2023 | +17.1% | +44.4% | +44.4% | |
| Q4 2022 | -12.1% | -0.9% | +11.5% | |
| Q3 2022 | +12.0% | -3.2% | -17.7% | |
| Q2 2022 | +10.0% | -0.8% | +30.0% | |
| Q1 2022 | +34.6% | +25.4% | +10.0% | |
| Q4 2021 | -8.6% | +2.3% | +0.0% | |
| Q3 2021 | +0.4% | +0.8% | +2.9% | |
| Q2 2021 | +0.6% | +3.6% | -12.0% | |
| Q1 2021 | +9.5% | +8.8% | +21.6% | |
| Q4 2020 | +7.9% | +6.1% | -21.1% | |
| Q3 2020 | +0.6% | -3.1% | +21.4% | |
| Q2 2020 | -3.1% | +0.3% | -5.6% | |
| Q1 2020 | +0.0% | +0.4% | +3.1% | |
| Q4 2019 | -4.1% | -14.2% | +20.3% | |
| Q3 2019 | -44.0% | -33.7% | -29.7% | |
| Q2 2019 | -8.9% | -10.2% | +2.5% | |
| Q1 2019 | -1.6% | -6.5% | -0.6% | |
| Q4 2018 | +10.7% | +4.3% | -9.1% | |
| Q3 2018 | -8.8% | -17.1% | -26.8% | |
| Q2 2018 | +2.1% | +6.1% | +8.7% | |
| Q4 2017 | -1.4% | +1.2% | +30.8% | |
| Q3 2017 | -2.1% | +16.9% | +9.2% | |
| Q2 2017 | -5.6% | +2.0% | -6.2% | |
| Q1 2017 | +8.6% | +10.4% | -8.9% | |
| Q4 2016 | +4.0% | -4.7% | -16.2% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro